An Extension Study of T-DM1 in Patients Previously Treated With TDM-1

Status: Recruiting
Phase:
Diagnosis: Breast: Early Stage Disease
NCT ID: NCT00781612 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 09-096

 

This is a multicenter, open-label extension study. Patients receiving T-DM1 in a Genentech-sponsored study who completed the parent study or who continue to receive T-DM1 at the time of the parent study closure are eligible for continued treatment on this protocol. The dose and schedule of T-DM1 administered will be that given in the parent study. Patients can receive T-DM1 until disease progression or unacceptable toxicity for as long as the extension study remains open. Patients randomized to non-T-DM1-containing treatment arms of T-DM1 trials are not eligible for this study.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital

Overall PI:
Ian Krop, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Steven Isakoff, MD, PhD, Massachusetts General Hospital

Contacts:
Dana-Farber Cancer Institute: Breast Cancer Nursing Team, 617-632-3478
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Completed T-DM1 treatment on the parent study or who continue to receive T-DM1 at the time of the parent study closure - Expectation by the investigator that the patient may continue to benefit from additional T-DM1 treatment - For women of childbearing potential, agreement to use an effective form of contraception (patient and/or partner, e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of the study. For men, agreement to use an effective form of contraception and to continue its use for the duration of the study. Exclusion Criteria: - Adverse events leading to T-DM1 discontinuation in the parent study - Ongoing serious adverse events from the parent study - Progressive disease during parent study or before starting the extension study - Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 - History of symptomatic congestive heart failure ([CHF]; New York Heart Association [NYHA] Classes II-IV), ventricular arrhythmia requiring treatment, or history of myocardial infarction within 6 months prior to study entry - Severe dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy - Current severe, uncontrolled systemic disease - Major surgical procedure or significant traumatic injury within 28 days prior to study entry or anticipation of the need for major surgery during the course of study treatment - Current pregnancy or lactation - History of receiving any investigational treatment or other systemic therapy directed at controlling cancer (i.e., chemotherapy, Herceptin�) since the patient's last dose in the parent study - History of hypersensitivity with previous T-DM1 treatment, precluding further dosing - Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms